Sensitivity analyses
DISEASE PROGRESSION, SENSITIVITY
Four (7.1%) of the MAG‐EPA patients received adjuvant treatment (i.e., hormone therapy and/or radiation therapy) during the course of the study, as compared to three patients (5.0%) in the placebo group. In addition, 7 MAG‐EPA patients (12.5%) experienced disease progression (e.g., PSA ≥ 0.2 ng/mL post‐RP, biochemical relapse), as compared to four patients (6.7%) in the placebo group. Sensitivity analyses excluding these patients did not significantly alter the study findings, nor its conclusions.